ArticleAmerican journal of cancer research2023

A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefit.

Chung-Wei Su et al.PubMed ↗Full text ↗

No numbers read from the abstract.